Skip to main content
EJNMMI Research

Table 5 Univariate analysis of factors predictive of progression-free and overall survival

From: Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL)

Variable

No. of patients (n = 84)

Progression-free survival

Overall survival

B

SE

Wald

HR (95% CI)

P value*

B

SE

Wald

HR (95% CI)

P value*

Sex, F/M

30/54

0.334

0.315

1.124

1.396 (0.753–2.588)

0.289

0.374

0.323

1.342

1.454 (0.772–2.738)

0.247

Age, ≤ 60/> 60

43/41

0.513

0.304

2.841

1.670 (0.920–3.032)

0.092

0.576

0.305

3.564

1.779 (0.978–3.236)

0.059

LDH level, normal/elevated

38/46

0.679

0.310

4.790

1.972 (1.073–3.621)

0.029

0.800

0.317

6.389

2.226 (1.197–4.141)

0.011

B symptoms, no/yes

33/51

0.861

0.334

6.662

2.366 (1.230–4.550)

0.010

0.840

0.341

6.072

2.317 (1.188–4.520)

0.014

ECOG PS, 0–1/≥ 2

57/27

1.055

0.300

12.337

2.873 (1.594–5.176)

< 0.001

0.999

0.301

10.986

2.715 (1.504–4.900)

0.001

Ann Arbor stage, I–II/III–IV

15/69

0.867

0.477

3.300

2.379 (0.934–6.059)

0.069

0.975

0.526

3.436

2.650 (0.946–7.429)

0.064

Extranodal sites ≥ 2, no/yes

65/19

0.545

0.321

2.880

1.724 (0.919–3.233)

0.090

0.494

0321

2.369

1.639 (0.874–3.075)

0.124

BMB, negative/positive

63/21

0.652

0.310

4.430

1.920 (1.046–3.525)

0.035

0.624

0.310

4.050

1.866 (1.016–3.427)

0.044

Ki-67 ≥ 80%, no/yes

60/24

0.556

0.305

3.334

1.744 (0.960–3.169)

0.068

0.517

0.306

2.854

1.678 (0.920–3.057)

0.091

Platelet cell count, ≥ 150 × 109/L

48/36

0.594

0.300

3.923

1.812 (1.006–3.262)

0.048

0.588

0.300

3.836

1.800 (1.000–3.240)

0.050

IPI, 0–2/3–5

47/37

1.148

0.313

13.475

3.153 (1.708–5.820)

< 0.001

1.143

0.314

13.287

3.136 (1.696–5.799)

< 0.001

PIT, 0–1/2–4

41/43

1.068

0.317

11.316

2.909 (1.561–5.418)

0.001

1.113

0.324

11.799

3.044 (1.613–5.744)

0.001

IPTCLP, 0–1/2, 3

54/30

1.027

0.304

11.445

2.793 (1.540–5.064)

0.001

0.999

0.304

10.763

2.715 (1.495–4.930)

0.001

SUVmax, low/high

22/62

0.959

0.405

5.619

2.609 (1.181–5.766)

0.018

1.020

0.421

5.878

2.773 (1.216–6.325)

0.015

TMTV, low/high

43/41

1.665

0.344

23.460

5.286 (2.695–10.369)

< 0.001

1.608

0.342

22.095

4.994 (2.554–9.766)

< 0.001

TLG, low/high

35/49

1.201

0.351

11.680

3.324 (1.669–6.620)

0.001

1.179

0.351

11.273

3.250 (1.633–6.467)

0.001

  1. Univariate analyses of factors predictive of survival in patients whose scans were evaluated using TMTV and TLG
  2. CI confidence interval, SE standard error, LDH lactate dehydrogenase, ECOG PS Eastern Cooperative Oncology Group performance status, BMB bone marrow biopsy, IPI International Prognostic Index, PIT prognostic index for T-cell lymphoma, IPTCLP International peripheral T cell lymphoma Project, TMTV total metabolic tumor volume, TLG total lesion glycolysis
  3. *P < 0.05
Back to article page